title: Efficacy and Safety of Onychomycosis Treatments: An Evidence-Based Overview.
abstract: Three systemic agents commonly are used for the treatment of onychomycosis. Until the introduction of ciclopirox in 1999, these were the only FDA-approved therapeutic options for managing these infections. With the recent approval of two new topical antifungal agents-efinaconazole in the azole class, and tavaborole, a unique boron-containing medication- clinicians and patients have an improved roster of medications for managing onychomycosis. Semin Cutan Med Surg 34(supp3):S46-S50 © 2015 published by Frontline Medical Communications.
authors.affiliation: Professor of Dermatology, Eastern Virginia Medical School, Department of Dermatology, Pariser Dermatology, Norfolk, Virginia.
authors.forename: David M
authors.initials: DM
authors.lastname: Pariser
keywords: Ciclopirox; dermatophyte infections; efinaconazole; fluconazole; itraconazole; laser therapy; onychomycosis; tavaborole; terbinafine